People

Vanessa Yen is a patent litigation partner on the Intellectual Property, Patent, Trademark and Copyright Litigation team.  She focuses on handling high stakes, complex patent litigation and litigation-related counseling in the biotech, life sciences and pharmaceutical industries, including in the Hatch-Waxman and biosimilars context.  Her experience includes litigating patent disputes in U.S. district court, the U.S. Court of Appeals for the Federal Circuit, and the PTAB.  Vanessa has represented both small and large international clients, including protecting the exclusivity of blockbuster products in bet-the-company litigation.  Having worked on a diverse range of products and technologies, her experience includes treatments for autoimmune disease, ADHD, COPD, eczema, epilepsy, rosacea, HIV, and schizophrenia.

Vanessa was part of the winning team that obtained the first victory on behalf of a pharmaceutical client in an inter partes review proceeding on an Orange Book-listed patent involved in parallel Hatch-Waxman litigation.  The PTAB upheld all challenged claims.

Vanessa is ranked by IAM Patents 1000 as a “top patent professional” with “exceptional skill sets and profound insights into patent matters.”  She is also a “Rising Star” and named as one of “The Top Women Attorneys in New York Metro” by Super Lawyers from 2014 to 2019.

Prior to practicing law, Vanessa received her B.S. in Biology from M.I.T. and conducted years of scientific research on the Human Genome Project when at M.I.T. and on human breast cancer while at Cold Spring Harbor Laboratory.

Full Bio

Credentials

J.D., Cornell Law School

B.S., Massachusetts Institute of Technology

New Jersey

New York

MFY Legal Services

National Association of Women Lawyers

New York Intellectual Property Law Association

Cantonese Hong Kong

Mandarin Chinese

Ranked a "Top Patent Professional"


IAM Patents 1000, 2019

Named a “Rising Star” in Intellectual Property Litigation


Super Lawyers, 2014-2019

Recognized as a “Top Women Attorneys in New York Metro”


Super Lawyers, 2014-2019

Icon close

Close

Recognition

Ranked a "Top Patent Professional"


IAM Patents 1000, 2019

Named a “Rising Star” in Intellectual Property Litigation


Super Lawyers, 2014-2019

Recognized as a “Top Women Attorneys in New York Metro”


Super Lawyers, 2014-2019

Matters

Obtained first victory for pharmaceutical client in an inter partes review proceeding in the Hatch-Waxman context, where the PTAB upheld all challenged claims on patents covering Oracea®, a multi-million dollar drug product

Obtained trial win for client Galderma in a multi-party Hatch Waxman litigation where its longest-running patent covering Oracea® was successfully upheld by the U.S. District Court of Delaware and by the Federal Circuit on appeal (per curium)

Obtained favorable non-institution decision from the PTAB on behalf of a pharmaceutical client Galderma for all three inter partes review petitions in the Hatch-Waxman context

See more
Icon close

Close

Matters

Obtained first victory for pharmaceutical client in an inter partes review proceeding in the Hatch-Waxman context, where the PTAB upheld all challenged claims on patents covering Oracea®, a multi-million dollar drug product

Obtained trial win for client Galderma in a multi-party Hatch Waxman litigation where its longest-running patent covering Oracea® was successfully upheld by the U.S. District Court of Delaware and by the Federal Circuit on appeal (per curium)

Obtained favorable non-institution decision from the PTAB on behalf of a pharmaceutical client Galderma for all three inter partes review petitions in the Hatch-Waxman context

Obtained favorable settlements on behalf of pharmaceutical client Galderma with multiple defendants seeking approval for generic versions of its Oracea® drug product

Served as litigation counsel for numerous pharmaceutical companies in defending their patents on multi-billion and multi-million dollar drug products, including:

Eisai Co., Ltd. in a Hatch-Waxman action involving Banzel® (rufinamide), an antiepileptic drug product

Sunovion Pharmaceuticals Inc. in a Hatch-Waxman action involving Brovana® (arformoterol), a chronic obstructive pulmonary disease drug product

Shire LLC and Supernus Pharmaceuticals, Inc. in a Hatch-Waxman action involving Intuniv® (extended-release guanfacine), a non-stimulant treatment for ADHD

Gilead Sciences in a Hatch-Waxman action involving Truvada® (emtricitabine and tenofovir disoproxil fumarate), an anti-HIV-1 drug product

Novartis Pharmaceuticals in a Hatch-Waxman action involving Trileptal® (oxcarbazepine), an anti-epileptic drug product for the treatment of partial seizures

UCB and Celltech Pharmaceuticals in a Hatch-Waxman action involving Metadate CD® (methylphenidate hydrochloride), an ADHD drug product

Matters

Obtained first victory for pharmaceutical client in an inter partes review proceeding in the Hatch-Waxman context, where the PTAB upheld all challenged claims on patents covering Oracea®, a multi-million dollar drug product

Obtained trial win for client Galderma in a multi-party Hatch Waxman litigation where its longest-running patent covering Oracea® was successfully upheld by the U.S. District Court of Delaware and by the Federal Circuit on appeal (per curium)

Obtained favorable non-institution decision from the PTAB on behalf of a pharmaceutical client Galderma for all three inter partes review petitions in the Hatch-Waxman context

See more
Icon close

Close

Matters

Obtained first victory for pharmaceutical client in an inter partes review proceeding in the Hatch-Waxman context, where the PTAB upheld all challenged claims on patents covering Oracea®, a multi-million dollar drug product

Obtained trial win for client Galderma in a multi-party Hatch Waxman litigation where its longest-running patent covering Oracea® was successfully upheld by the U.S. District Court of Delaware and by the Federal Circuit on appeal (per curium)

Obtained favorable non-institution decision from the PTAB on behalf of a pharmaceutical client Galderma for all three inter partes review petitions in the Hatch-Waxman context

Obtained favorable settlements on behalf of pharmaceutical client Galderma with multiple defendants seeking approval for generic versions of its Oracea® drug product

Served as litigation counsel for numerous pharmaceutical companies in defending their patents on multi-billion and multi-million dollar drug products, including:

Eisai Co., Ltd. in a Hatch-Waxman action involving Banzel® (rufinamide), an antiepileptic drug product

Sunovion Pharmaceuticals Inc. in a Hatch-Waxman action involving Brovana® (arformoterol), a chronic obstructive pulmonary disease drug product

Shire LLC and Supernus Pharmaceuticals, Inc. in a Hatch-Waxman action involving Intuniv® (extended-release guanfacine), a non-stimulant treatment for ADHD

Gilead Sciences in a Hatch-Waxman action involving Truvada® (emtricitabine and tenofovir disoproxil fumarate), an anti-HIV-1 drug product

Novartis Pharmaceuticals in a Hatch-Waxman action involving Trileptal® (oxcarbazepine), an anti-epileptic drug product for the treatment of partial seizures

UCB and Celltech Pharmaceuticals in a Hatch-Waxman action involving Metadate CD® (methylphenidate hydrochloride), an ADHD drug product

Credentials

J.D., Cornell Law School

B.S., Massachusetts Institute of Technology

New Jersey

New York

MFY Legal Services

National Association of Women Lawyers

New York Intellectual Property Law Association

Cantonese Hong Kong

Mandarin Chinese

Ranked a "Top Patent Professional"


IAM Patents 1000, 2019

Named a “Rising Star” in Intellectual Property Litigation


Super Lawyers, 2014-2019

Recognized as a “Top Women Attorneys in New York Metro”


Super Lawyers, 2014-2019

Icon close

Close

Recognition

Ranked a "Top Patent Professional"


IAM Patents 1000, 2019

Named a “Rising Star” in Intellectual Property Litigation


Super Lawyers, 2014-2019

Recognized as a “Top Women Attorneys in New York Metro”


Super Lawyers, 2014-2019